SEARCH:   Advanced

Blood, 10 September 2009, Vol. 114, No. 11, pp. 2232-2235. Prepublished online as a Blood First Edition Paper on June 16, 2009; DOI 10.1182/blood-2009-02-204693. This Article Full Text (PDF) All Versions of this Article: blood-2009-02-204693v1 114/11/2232    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Verma, D. Articles by Cortes, J. PubMed PubMed Citation Articles by Verma, D. Articles by Cortes, J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 10, 2009 Accepted June 7, 2009 Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance Dushyant Verma, Hagop M. Kantarjian, Dan Jones, Rajyalakshmi Luthra, Gautam Borthakur, Srdan Verstovsek, Mary Beth Rios, and Jorge Cortes* Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States * Corresponding author; email: jcortes{at}mdanderson.org. The most common BCR-ABL transcripts in CML are e13a2(b2a2) and e14a2(b3a2). Other transcripts like e1a2 are rare and their outcome with TKI therapy is undefined. We analyzed 1292 CML patients and identified 14 with only e1a2 transcripts, 9 in chronic (CP), 1 accelerated (AP), and 4 blast phase (BP). Of the CP, 4 achieved CHR, 2 CCyR, 2 PCyR, and 1 did not respond to imatinib. Five patients progressed to myeloid BP (3), lymphoid BP (1), or AP (1). The AP patient received various TKIs sequentially and achieved only CHR. BP patients received Hyper-CVAD+imatinib/dasatinib or idarubicin+Ara-C; 2 did not respond, 1 had CCyR, and 1 short-lasting CMR. Overall, cytogenetic responses lasted 3-18 months, only 2 achieved MMR on TKI. P190BCR-ABL CML is rare and is associated with an inferior outcome to therapy with TKI. These patients need to be identified as high-risk patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis Animesh Pardanani, Ayalew Tefferi, Mark R. Litzow, Clive Zent, William J. Hogan, Rebecca F. McClure, and David Viswanatha Blood 2009 114: 3502-3503. [Full Text] [PDF] This article has been cited by other articles: A. Pardanani, A. Tefferi, M. R. Litzow, C. Zent, W. J. Hogan, R. F. McClure, and D. Viswanatha Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis Blood, October 15, 2009; 114(16): 3502 - 3503. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020